Michael Schindler

Prof. Dr. Michael Schindler

Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Elfriede-Aulhorn-Str. 6, 72076 Tübingen, Germany
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2014 in Science
Verified
Journal Article
Closed access
PDF file
Julie LuciforaJulie Lucifora
Julie Lucifora
YXYuchen Xia
Yuchen Xia
FRFlorian Reisinger
Florian Reisinger
KZKe Zhang
Ke Zhang
DSDaniela Stadler
Daniela Stadler
Ulrike ProtzerUlrike Protzer
Ulrike Protzer
Clearance of Chronic Virus: The family of mRNA-editing enzymes, APOBEC, restricts hepatitis B virus (HBV) replication. Lucifora et al. (p. 1221 , published online 20 February; see the Perspective by Shlomai and Rice ) provide evidence that specific APOBECs mediate the anti-HBV effects of host cytokines, which in turn apparently induce nuclear deaminase activity without damaging host cells. Thus, there may be potential in these findings for developing a therapeutic route to curing chronic HBV infection.

1 December 2007 in Cell
Verified
Journal Article
Closed access
JMJan Münch
Jan Münch
ERElke Rücker
Elke Rücker
LSLudger Ständker
Ludger Ständker
KAKnut Adermann
Knut Adermann
CGChristine Goffinet
Christine Goffinet
FKFrank Kirchhoff
Frank Kirchhoff

1 November 2009 in Cell Host & Microbe
Verified
Journal Article
Closed access
DSDaniel Sauter
Daniel Sauter
MSMichael Schindler
Michael Schindler
ASAnke Specht
Anke Specht
WLWilmina N. Landford
Wilmina N. Landford
JMJan Münch
Jan Münch
FKFrank Kirchhoff
Frank Kirchhoff

12 February 2021 in Science
Verified
Journal Article
Open access
PDF file
PKPaul-Albert Koenig
Paul-Albert Koenig
HDHrishikesh Das
Hrishikesh Das
Hejun LiuHejun Liu
Hejun Liu
BKBeate M. Kümmerer
Beate M. Kümmerer
FGFlorian N. Gohr
Florian N. Gohr
FSFlorian Schmidt
Florian Schmidt
A double punch against SARS-CoV-2: Monoclonal antibodies are an important weapon in the battle against COVID-19. However, these large proteins are difficult to produce in the needed quantities and at low cost. Attention has turned to nanobodies, which are aptly named, single-domain antibodies that are easier to produce and have the potential to be administered by inhalation. Koenig et al. describe four nanobodies that bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent infection of cells (see the Perspective by Saelens and Schepens). Structures show that the nanobodies target two distinct epitopes on the SARS-CoV-2 spike protein. Multivalent nanobodies neutralize virus much more potently than single nanobodies, and multivalent nanobodies that bind two epitopes prevent the emergence of viral escape mutants. Science , this issue p. eabe6230 ; see also p. 681

1 June 2006 in Cell
Verified
Journal Article
Closed access
MSMichael Schindler
Michael Schindler
JMJan Münch
Jan Münch
OKOlaf Kutsch
Olaf Kutsch
HLHui Li
Hui Li
MSMario Santiago
Mario Santiago
FKFrank Kirchhoff
Frank Kirchhoff

4 October 2012 in Retrovirology
Verified
Journal Article
Open access
PDF file
HKHerwig Koppensteiner
Herwig Koppensteiner
RBRuth Brack-Werner
Ruth Brack-Werner
MSMichael Schindler
Michael Schindler
Macrophages are important target cells for the Human Immunodeficiency Virus Type I (HIV-1)in vivo. Several studies have assessed the molecular biology of the virus in this cell type, and a number of differences towards HIV-1 infection of CD4+ T cells have been described. There is a broad consensus that macrophages resist HIV-1 infection much better than CD4+ T cells. Among other reasons, this is due to the presence of the recently identified host cell restriction factor SamHD1, which is strongly expressed in cells of the myeloid lineage. Furthermore, macrophages produce and release relatively low amounts of infectious HIV-1 and are less sensitive to viral cytotoxicity in comparison to CD4+ T cells. Nevertheless, macrophages play a crucial role in the different phases of HIV-1 infection. In this review, we summarize and discuss the significance of macrophages for HIV-1 transmission, the acute and chronic phases of HIV-1 infection, the development of acquired immunodeficiency syndrome (AIDS) and HIV-associated diseases, including neurocognitive disorders. We propose that interaction of HIV-1 with macrophages is crucial during all stages of HIV-1 infection. Thus, long-term successful treatment of HIV-1 infected individuals requires potent strategies to prevent HIV-1 from entering and persisting in these cells.